Filing Flows › TransMedics Group (TMDX) › R&D spending
TransMedics Group (TMDX) R&D spending by quarter
TransMedics Group's R&D spending was $29.2M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $15.3M (Q3 2025) to $31.6M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $29.2M | -8% | +91% |
| Q2 2026 | $31.6M | +27% | +99% |
| Q1 2026 | $24.9M | +20% | +45% |
| Q4 2025 | $20.7M | +36% | — |
| Q3 2025 | $15.3M | -4% | — |
| Q2 2025 | $15.9M | -7% | — |
| Q1 2025 | $17.2M | — | — |
Q3 2026 at a glance
TransMedics Group, Q3 2026: revenue $203M (+41% year over year), operating margin 13.9%, net earnings $17.1M, operating cash flow $36.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is TransMedics Group's R&D spending?
TransMedics Group's R&D spending was $29.2M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has TransMedics Group's R&D spending changed?
Over the last 7 quarters it ranged from $15.3M (Q3 2025) to $31.6M (Q2 2026).